MCID: ADN009
MIFTS: 55

Adenosquamous Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 15 73
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 44
Carcinoma Adenosquamous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 44 D018196
NCIt 50 C3727
SNOMED-CT 68 59367005
UMLS 73 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to pancreatic adenosquamous carcinoma and adenosquamous lung carcinoma. An important gene associated with Adenosquamous Carcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, pancreas and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
# Related Disease Score Top Affiliating Genes
1 pancreatic adenosquamous carcinoma 33.7 KRAS PTHLH
2 adenosquamous lung carcinoma 31.9 EGFR KRAS PIK3CA
3 adenocarcinoma 30.5 EGFR KIT KRAS MUC1 MUC4 PIK3CA
4 adenoid squamous cell carcinoma 30.4 KRT7 KRT8
5 syringocystadenoma papilliferum 30.3 KRAS MUC1
6 cervical cancer 30.3 KRT5 PIK3CA TP53 TP63
7 cystic teratoma 30.2 KRT7 NKX2-1 TP53
8 in situ carcinoma 30.2 EGFR KRT5 TP53
9 mucoepidermoid carcinoma 30.1 EGFR KRT7 MUC1 MUC4 TP63
10 intestinal perforation 30.1 KRT7 NKX2-1
11 lynch syndrome 30.1 EGFR KRAS TP53
12 teratoma 30.1 KIT KRT7 NKX2-1 TP53
13 villous adenoma 30.0 KRAS KRT8 MUC1
14 squamous cell carcinoma 29.9 EGFR MUC1 PIK3CA PTHLH TP53 TP63
15 cystadenoma 29.9 KRT7 MUC1 MUC4
16 lymphoepithelioma-like carcinoma 29.9 KRT5 KRT7 KRT8 MUC1
17 hidradenoma 29.8 KRT7 MUC1 PIK3CA
18 gastrointestinal stromal tumor 29.8 EGFR KIT KRAS TP53
19 dermoid cyst 29.8 KIT KRT7 MUC1 TP63
20 large cell neuroendocrine carcinoma 29.8 EGFR KIT KRT7 NKX2-1
21 cystadenocarcinoma 29.7 KRT7 MUC1 PIK3CA TP53
22 mucinous adenocarcinoma 29.7 EGFR KRAS KRT7 MUC1 NKX2-1
23 carcinosarcoma 29.6 KIT KRAS KRT7 MUC1 PIK3CA TP53
24 necrotizing sialometaplasia 29.6 KIT KRT5 KRT7 TP53 TP63
25 small cell carcinoma 29.6 EGFR KIT KRT7 NKX2-1 TP53
26 papilloma 29.6 KRT5 KRT7 KRT8 TP53 TP63
27 gallbladder cancer 29.6 EGFR KRAS MUC1 PIK3CA TP53
28 small cell cancer of the lung 29.5 EGFR KIT KRT7 NKX2-1 PIK3CA TP53
29 endometrial cancer 29.1 AR EGFR KIT KRAS KRT7 PIK3CA
30 lung cancer 28.6 EGFR KIT KRAS KRT7 MUC4 NKX2-1
31 breast cancer 28.2 AR EGFR KIT KRAS KRT5 KRT8
32 glassy cell variant cervical adenosquamous carcinoma 12.4
33 endometrial adenosquamous carcinoma 12.4
34 gastric adenosquamous carcinoma 12.3
35 cervical adenosquamous carcinoma 12.3
36 esophageal adenosquamous carcinoma 12.3
37 thymus adenosquamous carcinoma 12.3
38 bartholin's gland adenosquamous carcinoma 12.2
39 ampulla of vater adenosquamous carcinoma 12.1
40 adenosquamous colon carcinoma 11.7
41 adenosquamous prostate carcinoma 11.6
42 adenosquamous gallbladder carcinoma 11.3
43 adenosquamous breast carcinoma 11.1
44 adenosquamous bile duct carcinoma 11.1
45 paronychia 10.3 EGFR KRAS
46 duodenum adenocarcinoma 10.3 KRAS KRT7
47 hepatoid adenocarcinoma 10.3 EGFR MUC1
48 appendix disease 10.3 KRAS KRT7
49 breast scirrhous carcinoma 10.3 EGFR MUC1
50 malignant peritoneal mesothelioma 10.3 EGFR MUC1

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.58 EGFR KRAS MUC1 PIK3CA
2 Decreased viability GR00106-A-0 9.58 KRAS
3 Decreased viability GR00221-A-1 9.58 EGFR KRAS PIK3CA
4 Decreased viability GR00221-A-2 9.58 KRAS PIK3CA
5 Decreased viability GR00221-A-4 9.58 EGFR PIK3CA
6 Decreased viability GR00301-A 9.58 KRAS
7 Decreased viability GR00381-A-1 9.58 KRAS
8 Decreased viability GR00402-S-2 9.58 EGFR KRAS MUC1 PIK3CA

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.32 AR EGFR KIT KRAS KRT8 NKX2-1
2 growth/size/body region MP:0005378 10.32 AR EGFR KIT KRAS KRT5 KRT8
3 cellular MP:0005384 10.31 AR EGFR KIT KRAS KRT7 NKX2-1
4 digestive/alimentary MP:0005381 10.3 AR EGFR KIT KRAS KRT5 KRT8
5 homeostasis/metabolism MP:0005376 10.3 AR EGFR KIT KRAS KRT7 KRT8
6 behavior/neurological MP:0005386 10.28 AR KIT KRAS KRT5 NKX2-1 PIK3CA
7 endocrine/exocrine gland MP:0005379 10.24 AR EGFR KIT KRAS NKX2-1 PIK3CA
8 mortality/aging MP:0010768 10.24 AR EGFR KIT KRAS KRT5 KRT8
9 craniofacial MP:0005382 10.21 AR EGFR KIT KRAS KRT5 PTHLH
10 immune system MP:0005387 10.2 AR EGFR KIT KRAS KRT8 PIK3CA
11 embryo MP:0005380 10.19 AR EGFR KIT KRAS KRT8 PIK3CA
12 integument MP:0010771 10.19 AR EGFR KIT KRAS KRT5 PIK3CA
13 limbs/digits/tail MP:0005371 10.13 AR EGFR KIT KRAS KRT5 PTHLH
14 neoplasm MP:0002006 10.11 AR EGFR KIT KRAS NKX2-1 PIK3CA
15 liver/biliary system MP:0005370 10.05 AR EGFR KIT KRAS KRT8 PTHLH
16 no phenotypic analysis MP:0003012 10.03 EGFR KIT KRAS KRT5 NKX2-1 PIK3CA
17 muscle MP:0005369 10.02 AR EGFR KIT KRAS PIK3CA TP53
18 normal MP:0002873 10.01 AR EGFR KIT KRAS NKX2-1 PTHLH
19 hearing/vestibular/ear MP:0005377 9.97 EGFR KIT KRAS KRT8 TP53
20 reproductive system MP:0005389 9.96 AR EGFR KIT KRAS KRT8 NKX2-1
21 renal/urinary system MP:0005367 9.92 AR EGFR KIT KRAS KRT7 PTHLH
22 pigmentation MP:0001186 9.77 AR EGFR KIT KRAS TP53
23 respiratory system MP:0005388 9.7 EGFR KIT KRAS NKX2-1 PTHLH TP53
24 skeleton MP:0005390 9.61 AR EGFR KIT KRAS NKX2-1 PIK3CA
25 vision/eye MP:0005391 9.17 EGFR KIT KRAS PIK3CA PTHLH TP53

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Vinblastine Approved Phase 3 865-21-4 241903 13342
11
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
12
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
13
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
14
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
15
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
16
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
17
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Mecasermin Approved, Investigational Phase 3 68562-41-4
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
21
Doxil Approved June 1999 Phase 3,Phase 1 31703
22
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
23 Immunologic Factors Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
26 Antibodies Phase 3,Phase 2,Phase 1
27 Immunoglobulins Phase 3,Phase 2,Phase 1
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
30 insulin Phase 3
31 Insulin, Globin Zinc Phase 3
32 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
33 Immunoglobulin G Phase 3,Phase 2,Phase 1
34 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
35 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
36 Mitogens Phase 3,Phase 2,Phase 1
37 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
38 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
39 Anti-Infective Agents Phase 3,Phase 2,Phase 1
40 Antiviral Agents Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
43 Antimetabolites Phase 3,Phase 2,Phase 1
44 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
45 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
46 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
47
Isophosphamide mustard Phase 3 0
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
49 Folic Acid Antagonists Phase 3,Phase 2
50 Alkylating Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
8 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
9 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
13 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
14 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
15 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
16 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
17 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
18 Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
19 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
20 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
21 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
22 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
23 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
24 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
25 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
26 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
27 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
28 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
29 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
30 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
31 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
32 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
33 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
34 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
35 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
36 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
37 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
38 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCT00030485 Phase 2 erlotinib hydrochloride
39 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
40 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
41 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
42 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
43 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
44 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
45 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
46 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
47 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
48 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
49 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
50 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

41
Cervix, Pancreas, Lung, Breast, Colon, Liver, Prostate

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 553)
# Title Authors Year
1
Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database. ( 29878370 )
2018
2
A retroperitoneal mass confirmed as a pancreatic adenosquamous carcinoma by endoscopic ultrasound-guided fine-needle aspiration. ( 29069702 )
2018
3
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. ( 29609906 )
2018
4
A Rare Case of Penile Metastases as a Harbinger of Primary Pulmonary Adenosquamous Carcinoma. ( 29785317 )
2018
5
High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. ( 29537649 )
2018
6
Clinicopathological characteristics and survival outcomes in adenosquamous carcinoma of the lung: a population-based study from the SEER database. ( 29487721 )
2018
7
Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes. ( 29850145 )
2018
8
Adenosquamous Carcinoma in the Midline Dorsum of the Tongue: A Rare Case Report. ( 29806990 )
2018
9
Pancreatic adenosquamous carcinoma masquerading as a locally invading splenic abscess. ( 29740918 )
2018
10
Long-term survival with extended lateral lymphadenectomy for lateral lymph node recurrence after laparoscopic abdominoperineal resection for rectal adenosquamous carcinoma: a case report. ( 29633041 )
2018
11
Adenosquamous carcinoma of the bile duct: a population-based study. ( 29563834 )
2018
12
Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. ( 30516569 )
2018
13
Colonic adenosquamous carcinoma and mucinous adenocarcinoma with microsatellite instability. ( 30173239 )
2018
14
Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report. ( 29983579 )
2018
15
Adenosquamous Carcinoma of the Esophagus: A Literature Review. ( 29984200 )
2018
16
Adenosquamous Carcinoma of the Ampulla of Vater: A Rare Cause of Obstructive Jaundice. ( 29998166 )
2018
17
Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. ( 30040455 )
2018
18
Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. ( 30100056 )
2018
19
Adenosquamous carcinoma of the right colon: A case report and review of the literature. ( 30103094 )
2018
20
Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. ( 30122989 )
2018
21
"Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features. ( 30138216 )
2018
22
Adenosquamous carcinoma of the lung. ( 30147334 )
2018
23
Adenosquamous carcinoma arising in a duplication cyst of the gallbladder. ( 30221164 )
2018
24
Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases. ( 30258209 )
2018
25
Survival analysis for lung adenosquamous carcinoma patients with brain metastasis. ( 30405840 )
2018
26
Research progress of the clinicopathologic features of lung adenosquamous carcinoma. ( 30410358 )
2018
27
Adenosquamous carcinoma of the papilla of Vater: A phenotypic heterogeneity characterized by a common molecular landscape. ( 30417956 )
2018
28
Low-grade Adenosquamous Carcinoma of the Breast: A Case Report. ( 30449342 )
2018
29
Adenosquamous Carcinoma of the Anus: An Uncommon Malignancy Presenting a Treatment Challenge. ( 30454337 )
2018
30
PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. ( 30477643 )
2018
31
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. ( 28848104 )
2017
32
Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor: a case of a rare malignancy. ( 28493097 )
2017
33
Adenosquamous Carcinoma of the Pancreas Demonstrated on 18F-FDG PET/CT Imaging. ( 28098663 )
2017
34
Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. ( 28123305 )
2017
35
Primary Hepatic Adenosquamous Carcinoma Associated with Primary Sclerosing Cholangitis. ( 29258074 )
2017
36
Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast: A case report. ( 29145336 )
2017
37
CD117 expression in adenosquamous carcinoma. ( 28766737 )
2017
38
Genomic signatures of pancreatic adenosquamous carcinoma (PASC). ( 28722109 )
2017
39
Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: A preliminary report. ( 28784574 )
2017
40
Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a<i>CDKN2A</i>germline mutation carrier. ( 28979722 )
2017
41
Importance of tumor extent in adenosquamous carcinoma of the head and neck: a retrospective cohort study. ( 28412233 )
2017
42
Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report. ( 28357109 )
2017
43
Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. ( 28816351 )
2017
44
Clinicopathological features and prognosis of gastric adenosquamous carcinoma. ( 28676632 )
2017
45
Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 28465645 )
2017
46
Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )
2017
47
The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma. ( 28397462 )
2017
48
Spontaneous pulmonary adenosquamous carcinoma in a free-living black capuchin monkey (Sapajus nigritus). ( 29283438 )
2017
49
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. ( 29203990 )
2017
50
Adenosquamous Carcinoma of the Colon. ( 29606937 )
2017

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 EGFR KIT KRAS KRT5 KRT7 KRT8
2
Show member pathways
13.25 EGFR KIT KRAS MUC1 PIK3CA TP53
3
Show member pathways
12.86 EGFR KIT KRAS PIK3CA TP53
4
Show member pathways
12.81 EGFR KIT KRAS PIK3CA TP53
5
Show member pathways
12.56 EGFR KIT KRAS PIK3CA TP53
6
Show member pathways
12.51 EGFR KIT KRAS PIK3CA TP53
7
Show member pathways
12.47 EGFR KRAS PIK3CA TP53
8 12.4 KRT5 KRT7 KRT8 MUC1
9
Show member pathways
12.38 AR EGFR KIT KRAS PIK3CA TP53
10
Show member pathways
12.35 EGFR KRAS PIK3CA TP53
11
Show member pathways
12.33 EGFR KRAS PIK3CA TP53
12
Show member pathways
12.28 EGFR KRAS PIK3CA TP53
13
Show member pathways
12.25 EGFR KRAS MUC1 PIK3CA TP53
14
Show member pathways
12.21 EGFR KIT KRAS PIK3CA
15
Show member pathways
12.15 EGFR KIT KRAS TP53
16 12.15 AR EGFR KIT KRAS PIK3CA TP53
17 12.13 EGFR KRAS PIK3CA TP53 TP63
18 12.11 EGFR KRAS PIK3CA TP53
19
Show member pathways
12.05 EGFR KRAS PIK3CA TP53
20
Show member pathways
12 EGFR KRAS PIK3CA
21 11.97 EGFR TP53 TP63
22
Show member pathways
11.94 EGFR PIK3CA TP53
23 11.92 AR EGFR KRAS TP53
24 11.91 KRAS PIK3CA TP53
25 11.91 EGFR KRAS PIK3CA TP53
26 11.9 KRAS PIK3CA TP53
27 11.88 KRAS PIK3CA TP53
28 11.86 EGFR KRAS TP53
29
Show member pathways
11.84 KRT5 KRT7 KRT8
30
Show member pathways
11.83 EGFR KRAS PIK3CA
31 11.82 EGFR KRAS PIK3CA TP53
32 11.79 EGFR KRAS PIK3CA
33
Show member pathways
11.74 EGFR KRAS PIK3CA
34
Show member pathways
11.67 KIT KRAS PIK3CA
35 11.58 EGFR KRAS TP53
36 11.19 EGFR KRAS TP53
37 10.96 EGFR PIK3CA
38 10.93 AR PIK3CA
39 10.93 EGFR KRAS PIK3CA
40 10.83 EGFR KIT KRAS PIK3CA TP53

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.4 AR EGFR KIT KRAS KRT5 KRT7
2 keratin filament GO:0045095 9.33 KRT5 KRT7 KRT8
3 nuclear chromatin GO:0000790 9.26 AR MUC1 TP53 TP63

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.88 AR EGFR TP53 TP63
2 positive regulation of transcription, DNA-templated GO:0045893 9.88 AR EGFR NKX2-1 TP53 TP63
3 positive regulation of cell proliferation GO:0008284 9.8 AR EGFR KIT KRAS PTHLH
4 positive regulation of MAPK cascade GO:0043410 9.77 AR EGFR KIT
5 phosphatidylinositol phosphorylation GO:0046854 9.73 EGFR KIT PIK3CA
6 cornification GO:0070268 9.72 KRT5 KRT7 KRT8
7 positive regulation of gene expression GO:0010628 9.65 AR KIT KRAS NKX2-1 TP53
8 liver development GO:0001889 9.63 EGFR KRAS PIK3CA
9 epithelial tube branching involved in lung morphogenesis GO:0060441 9.58 KRAS NKX2-1
10 prostate gland development GO:0030850 9.57 AR TP63
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.54 MUC1 TP53
12 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.54 KRAS MUC1 MUC4
13 tongue development GO:0043586 9.52 EGFR KIT
14 cerebral cortex cell migration GO:0021795 9.51 EGFR NKX2-1
15 positive regulation of MAP kinase activity GO:0043406 9.5 EGFR KIT KRAS
16 Leydig cell differentiation GO:0033327 9.49 AR NKX2-1
17 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 EGFR TP53
18 cytokine-mediated signaling pathway GO:0019221 9.35 KIT KRAS MUC1 PIK3CA TP53
19 morphogenesis of an epithelial fold GO:0060571 9.16 AR EGFR
20 epidermis development GO:0008544 8.92 EGFR KRT5 PTHLH TP63

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.56 AR EGFR NKX2-1 TP53
2 transcription regulatory region DNA binding GO:0044212 9.46 AR NKX2-1 TP53 TP63
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 EGFR KIT PIK3CA
4 p53 binding GO:0002039 8.8 MUC1 TP53 TP63

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....